CHMP recommends Lilly and Boehringer Ingelheim’s Lantus biosimilar

June 30, 2014 6:44 AM

Last Friday, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.

The new insulin glargine product from Eli Lilly and Company and Boehringer Ingelheim is the first biosimilar insulin recommended for approval in the European Union.

Lilly/BI’s insulin glargine is a basal insulin, which is intended to provide long-lasting blood sugar control between meals and at night, an integral part of glycemic control. It has the same amino acid sequence as Lantus (insulin glargine) and was filed through the European Medicines Agency’s (EMA) biosimilar pathway.

As the term is a regulatory designation, Lilly/BI’s insulin glargine is considered a biosimilar in some regions, including Europe, but not in others, including the United States.

“The CHMP’s recommendation brings us a step closer to providing an important new option for the millions of patients in the EU who need basal insulin to help manage their diabetes,” said Enrique Conterno, president, Lilly Diabetes. “This first-ever biosimilar insulin to receive a positive CHMP recommendation underscores Lilly and Boehringer Ingelheim’s commitment to providing physicians and patients high-quality diabetes medicines, along with expertise and support tools they need to help manage the disease.”

The CHMP’s recommendation is based on the companies’ non-clinical and clinical development program, which included pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in patients with type 1 and type 2 diabetes.The European Commission’s final decision is expected in approximately two months. If approved for marketing authorisation, Lilly/BI’s insulin glargine would be the fourth diabetes product in the Lilly-Boehringer Ingelheim Diabetes Alliance to receive regulatory approval in the EU.

Source: Eli Lilly press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!